Target intelligence / Profile preview

Corneal tissue

Molecular classification
Connective tissue, Extracellular matrix, Collagen family (type I, V, VI, XII, XIV), Small leucine-rich proteoglycan family (decorin, lumican, keratocan, biglycan), Epithelial cell markers, Keratocytes, Endothelial cells
01

Overview

The corneal tissue consists of five main layers: the *epithelium* (regenerative protective surface), *Bowman's layer* (collagenous acellular barrier), *stroma* (collagen-rich connective tissue for transparency and strength), *Descemet's membrane* (basement membrane for endothelium), and *endothelium* (monolayer regulating hydration)[5][6]. The stroma comprises mainly type I and V collagen fibrils, organized to minimize light scattering, interspersed with keratocytes and small leucine-rich proteoglycans (lumican, decorin, keratocan, biglycan)[1][2][3][4]. Its primary biological role is maintaining vision by providing a transparent, strong, and smooth surface for light entry. As a tissue or organ, "corneal tissue" cannot be considered a precise molecular therapeutic target; rather, its individual molecular components (e.g., collagen, proteoglycans, ion channels) may serve as therapeutic, diagnostic, or research targets.

Other names
CorneaCorneal stroma (when referring to its main layer)Corneal epithelium (for its outer layer)
02

Mechanism of action

Not specific to a molecule; actions depend on drug class Antibiotics: inhibit bacterial growth at the corneal surface Corticosteroids: reduce inflammatory cytokine production Immunomodulators: suppress T-cell mediated inflammation

03

Biological functions

Maintenance of transparency for visionStructural integrity and protectionRefractive powerRegulation of extracellular matrix and hydrationWound healing and barrier function
04

Disease associations

Tissue-level diseasesKeratoconus (corneal thinning and distortion)Corneal dystrophies (inherited opacity)Infection (microbial keratitis)Inflammation (keratitis, immune-mediated disease)Scarring (post-trauma or surgery)
05

Safety considerations

Potential toxicity or damage to corneal cells (epithelial, stromal, endothelial) with drugs, preservatives, UV exposureRisk of corneal thinning, scarring, infection, impaired healing with inappropriate therapy
06

Interacting drugs

Antibiotics (e.g., moxifloxacin) for infection

3 more in the full profile.

07

Biomarkers

No canonical molecular biomarkers associated with "corneal tissue" as a whole; specific biomarkers may exist for diseases (e.g., keratocyte markers like lumican, keratocan, decorin)

Beyond the preview

Go deeper on Corneal tissue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corneal tissue.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call